Bristol-Myers Squibb Co., of New York, stopped an open-label, randomized phase III study evaluating Opdivo vs. docetaxel in previously treated patients with advanced, squamous cell non-small cell lung cancer because an assessment conducted by the independent data monitoring committee concluded that the study met its endpoint, demonstrating superior overall survival in patients receiving Opdivo compared to the control arm.